Evangelos Digkas
Physician at Department of Immunology, Genetics and Pathology; Clinical units; Clinical genetics
- E-mail:
- evangelos.digkas@igp.uu.se
- Visiting address:
- Dag Hammarskjölds väg 20
751 85 Uppsala - Postal address:
- Rudbecklaboratoriet
751 85 Uppsala
Researcher at Department of Immunology, Genetics and Pathology; Research programme: Cancer Immunotherapy; Research group Gustav Ullenhag
- E-mail:
- evangelos.digkas@igp.uu.se
- Visiting address:
- Akademiska sjukhuset, ingång 100/101
751 85 Uppsala - Postal address:
- Akademiska sjukhuset, ingång 100/101
751 85 Uppsala
Publications
Recent publications
-
Part of Cancer Immunology and Immunotherapy, 2025
- DOI for Differences in immune-related toxicity between PD-1 and PD-L1 inhibitors: a retrospective cohort study in patients with advanced cancer
- Download full text (pdf) of Differences in immune-related toxicity between PD-1 and PD-L1 inhibitors: a retrospective cohort study in patients with advanced cancer
-
Part of The Breast, 2025
- DOI for Genomic characterization and molecular predictive biomarkers for chemotherapy in patients with metastatic triple-negative breast cancer treated in a real-world setting
- Download full text (pdf) of Genomic characterization and molecular predictive biomarkers for chemotherapy in patients with metastatic triple-negative breast cancer treated in a real-world setting
-
Part of Frontiers in Oncology, 2024
- DOI for Multiple immune-related adverse events secondary to checkpoint inhibitor therapy in patients with advanced cancer: association with treatment effectiveness
- Download full text (pdf) of Multiple immune-related adverse events secondary to checkpoint inhibitor therapy in patients with advanced cancer: association with treatment effectiveness
-
Part of Breast Cancer Research and Treatment, p. 79-87, 2024
- DOI for Incidence and risk factors of hypothyroidism after treatment for early breast cancer: a population-based cohort study
- Download full text (pdf) of Incidence and risk factors of hypothyroidism after treatment for early breast cancer: a population-based cohort study
-
Part of Pigment Cell & Melanoma Research, 2024
- DOI for The role of dacarbazine and temozolomide therapy after treatment with immune checkpoint inhibitors in malignant melanoma patients: A case series and meta-analysis
- Download full text (pdf) of The role of dacarbazine and temozolomide therapy after treatment with immune checkpoint inhibitors in malignant melanoma patients: A case series and meta-analysis
All publications
Articles in journal
-
Part of Cancer Immunology and Immunotherapy, 2025
- DOI for Differences in immune-related toxicity between PD-1 and PD-L1 inhibitors: a retrospective cohort study in patients with advanced cancer
- Download full text (pdf) of Differences in immune-related toxicity between PD-1 and PD-L1 inhibitors: a retrospective cohort study in patients with advanced cancer
-
Part of The Breast, 2025
- DOI for Genomic characterization and molecular predictive biomarkers for chemotherapy in patients with metastatic triple-negative breast cancer treated in a real-world setting
- Download full text (pdf) of Genomic characterization and molecular predictive biomarkers for chemotherapy in patients with metastatic triple-negative breast cancer treated in a real-world setting
-
Part of Frontiers in Oncology, 2024
- DOI for Multiple immune-related adverse events secondary to checkpoint inhibitor therapy in patients with advanced cancer: association with treatment effectiveness
- Download full text (pdf) of Multiple immune-related adverse events secondary to checkpoint inhibitor therapy in patients with advanced cancer: association with treatment effectiveness
-
Part of Breast Cancer Research and Treatment, p. 79-87, 2024
- DOI for Incidence and risk factors of hypothyroidism after treatment for early breast cancer: a population-based cohort study
- Download full text (pdf) of Incidence and risk factors of hypothyroidism after treatment for early breast cancer: a population-based cohort study
-
Part of Pigment Cell & Melanoma Research, 2024
- DOI for The role of dacarbazine and temozolomide therapy after treatment with immune checkpoint inhibitors in malignant melanoma patients: A case series and meta-analysis
- Download full text (pdf) of The role of dacarbazine and temozolomide therapy after treatment with immune checkpoint inhibitors in malignant melanoma patients: A case series and meta-analysis
-
Part of Cancer Medicine, p. 13217-13224, 2023
- DOI for Predicting immune-related adverse events using a simplified frailty score in cancer patients treated with checkpoint inhibitors: A retrospective cohort study
- Download full text (pdf) of Predicting immune-related adverse events using a simplified frailty score in cancer patients treated with checkpoint inhibitors: A retrospective cohort study
Articles, review/survey
-
Part of Targeted oncology, p. 507-515, 2022
- DOI for Randomized Versus Real-World Evidence on the Efficacy and Toxicity of Checkpoint Inhibitors in Cancer in Patients with Advanced Non-small Cell Lung Cancer or Melanoma: A Meta-analysis
- Download full text (pdf) of Randomized Versus Real-World Evidence on the Efficacy and Toxicity of Checkpoint Inhibitors in Cancer in Patients with Advanced Non-small Cell Lung Cancer or Melanoma: A Meta-analysis